SELLAS Life Sciences Group, Inc with ticker code (SLS) have now 2 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 12 and 8 with the average target price sitting at 10. With the stocks previous close at 7.07 this is indicating there is a potential upside of 41.4%. The 50 day MA is 4.54 and the 200 moving average now moves to 3.24. The market capitalisation for the company is $100m. Visit the company website at: http://www.sellaslifesciences.com
The potential market cap would be $142m based on the market concensus.
SELLAS Life Sciences Group, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S that is in Phase 2b clinical trials for the treatment of breast cancer. The company has strategic collaboration with Merck & Co. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group was founded in 2012 and is headquartered in New York, New York.
